Different Definitions in Intention-to-treat Analysis for Chimeric Antigen Receptor T-cell Therapy Depend on Research Scope
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Di Staso R, Casadei B, Gentilini M, Guadagnuolo S, Pellegrini C, Broccoli A
. Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity. Ann Hematol. 2024; 103(7):2499-2509.
PMC: 11224113.
DOI: 10.1007/s00277-024-05766-0.
View
2.
Hu B, Vaidya R, Ahmed F, Ehsan H, Moyo T, Jacobs R
. Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma. Transplant Cell Ther. 2024; 30(11):1082.e1-1082.e10.
DOI: 10.1016/j.jtct.2024.09.007.
View
3.
Di Staso R, Casadei B, Locke F, Jain M, Voorhees T, Kittai A
. Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma. Blood Cancer J. 2024; 14(1):197.
PMC: 11544145.
DOI: 10.1038/s41408-024-01183-8.
View
4.
Milrod C, Steuer R, Pelcovits A
. Defining 'Intention' in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy. Blood Cancer J. 2025; 15(1):16.
PMC: 11807103.
DOI: 10.1038/s41408-025-01220-0.
View